Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 11, 2009Transfusion

Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non‐Hodgkin's lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

DYDok Hyun YoonUlsan CollegeBSByeong Seok SohnInje UniversityEKEun Kyoung KimInje University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Yoon et al. (2009) studied this question.

synapsesocial.com/papers/6aa91fccd0c7c778ac8cb274https://doi.org/10.1111/j.1537-2995.2009.02202.x
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Minimal number of circulating CD34+ cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation1998 · 93 citations
  2. 2Infused CD34<sup>+</sup> cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B‐cell lymphoma and follicular lymphoma grade 3 treated with high‐dose therapy2004 · 56 citations
  3. 3Revised Response Criteria for Malignant Lymphoma2007 · 4,467 citations
  4. 4Higher Infused Lymphocyte Dose Predicts Higher Lymphocyte Recovery, Which in Turn, Predicts Superior Overall Survival following Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma2007 · 87 citations